Ovarian cancer in endometriosis: clinical and molecular aspects.
Ovarian cancer in endometriosis: clinical and molecular aspects.
复制标题
DOI：
--
复制
发表时间：
2014-04
影响因子：
1
通讯作者：
B. Lyttle;L. Bernardi;M. Pavone
中科院分区：
文献类型：
--
作者：
B. Lyttle;L. Bernardi;M. Pavone
子宫内膜异位症是一种妇科疾病，其特征在于特定的组织学，分子和临床表现，影响5-10%的绝经前妇女，并被认为是某些类型卵巢癌的前兆。子宫内膜异位症相关性卵巢癌（EAOC）的临床研究表明，患者年龄较小，肿瘤分期和分级较低，并且比其他卵巢癌患者更可能处于绝经前。然而，当比较这些类型的卵巢癌之间的总生存率时，没有发现差异。此外，EAOC肿瘤更可能与癌症（最常见的是子宫内膜癌）同时诊断。技术的进步，主要是全基因组测序的能力，已经导致发现新的突变，并进一步了解以前鉴定的与EAOC相关的基因和途径，包括PTEN，CTNNB 1（β-连环蛋白），KRAS，微卫星不稳定性和ARID 1A。本文就子宫内膜异位症与卵巢癌关系的最新临床和分子生物学研究进展作一综述。
Endometriosis is a gynecological condition characterized by specific histological, molecular and clinical findings, that affects 5-10% of premenopausal women and has been implicated as a precursor for certain types of ovarian cancer. Clinical studies of endometriosis associated ovarian cancer (EAOC) suggest that patients present at a young age with a lower stage and grade of tumor, and are more likely to be premenopausal than women with other ovarian cancers. However, when overall survival is compared between these types of ovarian cancers, there is no difference noted. In addition, EAOC tumors are more likely to be found with a concurrent diagnosis of cancer, most commonly endometrial. Advances in technology, primarily the ability for whole genome sequencing, have led to the discovery of new mutations and further understanding of previously identified genes and pathways associated with EAOCs including PTEN, CTNNB1 (beta-catenin), KRAS, microsatellite instability and ARID1A. This paper will review the most recent clinical and molecular advances in the association of endometriosis and ovarian cancer.